- Page 1 and 2: Marijuana and the Cannabinoids Edit
- Page 3 and 4: F O R E N S I C SCIENCE AND MEDICIN
- Page 5: © 2007 Humana Press Inc. 999 River
- Page 9 and 10: viii Contents CHAPTER 7 Immunoassay
- Page 11 and 12: x Contributors MICHAEL L. SMITH, Ph
- Page 13 and 14: 2 Watson and Clarke wild and feral
- Page 15 and 16: 4 Watson and Clarke of North Americ
- Page 17 and 18: 6 Watson and Clarke Fig. 2. Microsc
- Page 19 and 20: 8 Watson and Clarke Fig. 3. Cannabi
- Page 21 and 22: 10 Watson and Clarke Fig. 4. The fo
- Page 23 and 24: 12 Watson and Clarke and contains v
- Page 25 and 26: 14 Watson and Clarke to develop nov
- Page 27 and 28: 16 Watson and Clarke
- Page 29 and 30: 18 Brenneisen Table 1 Cannabinoids
- Page 31 and 32: 20 Brenneisen Table 1 (continued) (
- Page 33 and 34: 22 Brenneisen Table 1 (continued) (
- Page 35 and 36: 24 Brenneisen Table 1 (continued) (
- Page 37 and 38: 26 Brenneisen Table 1 (continued) (
- Page 39 and 40: 28 Brenneisen 1.2. Noncannabinoid-T
- Page 41 and 42: 30 Brenneisen Table 2 (continued) (
- Page 43 and 44: 32 Brenneisen Table 2 (continued) a
- Page 45 and 46: 34 Brenneisen Table 2 (continued) (
- Page 47 and 48: 36 Brenneisen Table 3 Spermidine Al
- Page 49 and 50: 38 Brenneisen Table 6 C- and O-Glyc
- Page 51 and 52: 40 Brenneisen Table 7 Unsaturated F
- Page 53 and 54: 42 Brenneisen morphology and habit
- Page 55 and 56: 44 Brenneisen 10. ElSohly, M. (2002
- Page 57 and 58:
46 Brenneisen 55. Wachtel, S. R., E
- Page 59 and 60:
48 Brenneisen 96. Baker, P. B., Gou
- Page 61 and 62:
50 Brenneisen
- Page 63 and 64:
52 ElSohly et al. port other types
- Page 65 and 66:
54 ElSohly et al. state, or any oth
- Page 67 and 68:
56 ElSohly et al. 4. EXPERIMENTAL D
- Page 69 and 70:
58 ElSohly et al. presumed to be ho
- Page 71 and 72:
60 ElSohly et al. Table 2 Correct C
- Page 73 and 74:
62 ElSohly et al. 6.7. Application
- Page 75 and 76:
64 ElSohly et al. Since the complet
- Page 77 and 78:
66 ElSohly et al. 34. Brenneisen, R
- Page 79 and 80:
68 ElSohly and ElSohly one puff per
- Page 81 and 82:
70 ElSohly and ElSohly Chrom Q. For
- Page 83 and 84:
72 ElSohly and ElSohly considerable
- Page 85 and 86:
74 ElSohly and ElSohly Table 1 (con
- Page 87 and 88:
76 ElSohly and ElSohly Table 1 (con
- Page 89 and 90:
78 ElSohly and ElSohly Table 1 (con
- Page 91 and 92:
80 ElSohly and ElSohly Table 1 (con
- Page 93 and 94:
82 ElSohly and ElSohly Table 1 (con
- Page 95 and 96:
84 ElSohly and ElSohly Table 1 (con
- Page 97 and 98:
86 ElSohly and ElSohly Table 1 (con
- Page 99 and 100:
88 ElSohly and ElSohly Table 1 (con
- Page 101 and 102:
90 ElSohly and ElSohly Table 1 (con
- Page 103 and 104:
92 ElSohly and ElSohly Table 1 (con
- Page 105 and 106:
94 ElSohly and ElSohly pete with es
- Page 107 and 108:
96 ElSohly and ElSohly 30. Lares, A
- Page 109 and 110:
98 Raymon and Walls Fig. 1. Metabol
- Page 111 and 112:
100 Raymon and Walls Fig. 3. CB 1 r
- Page 113 and 114:
102 Raymon and Walls Fig. 4. Role o
- Page 115 and 116:
104 Raymon and Walls with excessive
- Page 117 and 118:
106 Raymon and Walls Fig. 8. Cerebe
- Page 119 and 120:
108 Raymon and Walls Fig. 9. The li
- Page 121 and 122:
110 Raymon and Walls control of foo
- Page 123 and 124:
112 Raymon and Walls Pain transmiss
- Page 125 and 126:
114 Raymon and Walls Fig. 12. The r
- Page 127 and 128:
116 Raymon and Walls The effects of
- Page 129 and 130:
118 Raymon and Walls shed light on
- Page 131 and 132:
120 Raymon and Walls drocannabinol-
- Page 133 and 134:
122 Raymon and Walls 78. Budney, A.
- Page 135 and 136:
124 Raymon and Walls
- Page 137 and 138:
126 Martin to demand more effective
- Page 139 and 140:
128 Martin same time, the functiona
- Page 141 and 142:
130 Martin As for clinical evidence
- Page 143 and 144:
132 Martin Rectal suppositories of
- Page 145 and 146:
134 Martin implanted with morphine
- Page 147 and 148:
136 Martin 2. Grinspoon, L. and Bak
- Page 149 and 150:
138 Martin 40. Bisogno, T., Howell,
- Page 151 and 152:
140 Martin 76. Welch, S. P. and Ste
- Page 153 and 154:
142 Martin 116. Justinova, Z., Tand
- Page 155 and 156:
144 Martin
- Page 157 and 158:
146 Tsai requirements and challenge
- Page 159 and 160:
148 Tsai of polarization. Calibrato
- Page 161 and 162:
150 Tsai 2.3. Point-of-Collection D
- Page 163 and 164:
152 Tsai Fig. 1. Chemical structure
- Page 165 and 166:
154 Tsai tion of drug use. Most com
- Page 167 and 168:
156 Tsai Fig. 3. Immunogen strategi
- Page 169 and 170:
158 Tsai immunoassay test to elimin
- Page 171 and 172:
160 Tsai is sufficiently above the
- Page 173 and 174:
162 Fig. 4. Relative concentrations
- Page 175 and 176:
164 Tsai GC/MS analysis to ensure t
- Page 177 and 178:
166 Tsai Recently, Skopp and collea
- Page 179 and 180:
168 Tsai Deliberate invalidation of
- Page 181 and 182:
170 Tsai 3. United Nations Internat
- Page 183 and 184:
172 Tsai 41. Yang, J. M. and Lewand
- Page 185 and 186:
174 Tsai 81. Gustafson, R. A., Mool
- Page 187 and 188:
176 Tsai and suggested cutoff conce
- Page 189 and 190:
178 Tsai 156. Wong, R. (2002) The e
- Page 191 and 192:
180 Foltz standards. However, canna
- Page 193 and 194:
182 Foltz 4. DETERMINATION OF CANNA
- Page 195 and 196:
184 Foltz and HO-THC (m/z 475) were
- Page 197 and 198:
186 Foltz EI-GC/MS with selected io
- Page 199 and 200:
188 Foltz NaOH (1-2 N) at 80-95°C
- Page 201 and 202:
190 Table 1 (continued) LOQ LOD Ref
- Page 203 and 204:
192 Table 2 Published Methods for M
- Page 205 and 206:
194 Table 4 Published Method for Ma
- Page 207 and 208:
196 Table 6 Published Methods for M
- Page 209 and 210:
198 Table 7 (continued) LOQ LOD Ref
- Page 211 and 212:
200 Foltz 7. ElSohly, M. A., Little
- Page 213 and 214:
202 Foltz 42. Gustafson, R. A., Moo
- Page 215 and 216:
204 Foltz 79. Collins, M., Easson,
- Page 217 and 218:
206 Huestis and Smith In this chapt
- Page 219 and 220:
208 Huestis and Smith Fig. 1. Mean
- Page 221 and 222:
210 Huestis and Smith tration compa
- Page 223 and 224:
212 Huestis and Smith trolled, rand
- Page 225 and 226:
214 Huestis and Smith assay (RIA),
- Page 227 and 228:
216 Huestis and Smith our example.
- Page 229 and 230:
218 Huestis and Smith States progra
- Page 231 and 232:
220 Huestis and Smith Fig. 7. Gener
- Page 233 and 234:
222 Huestis and Smith Services Admi
- Page 235 and 236:
224 Huestis and Smith for drugs of
- Page 237 and 238:
226 Huestis and Smith Furthermore,
- Page 239 and 240:
228 Huestis and Smith frame of days
- Page 241 and 242:
230 Huestis and Smith 30. Huestis,
- Page 243 and 244:
232 Huestis and Smith 69. Huestis,
- Page 245 and 246:
234 Huestis and Smith 105. Gronholm
- Page 247 and 248:
236 Huestis and Smith
- Page 249 and 250:
238 Khalsa Marijuana use has been r
- Page 251 and 252:
240 Khalsa individuals to pulmonary
- Page 253 and 254:
242 Khalsa gonadal axis (37) or, in
- Page 255 and 256:
244 Khalsa cannabis for an average
- Page 257 and 258:
246 Khalsa included grooming, retro
- Page 259 and 260:
248 Khalsa logical and experimental
- Page 261 and 262:
250 Khalsa 21. Tashkin, D.P., Baldw
- Page 263 and 264:
252 Khalsa 61. Gruber, A. J. and Po
- Page 265 and 266:
254 Tashkin and Roth Fig. 1. Habitu
- Page 267 and 268:
256 Tashkin and Roth Table 1 Pulmon
- Page 269 and 270:
258 Tashkin and Roth (33). Marijuan
- Page 271 and 272:
260 Tashkin and Roth Fig. 3. The nu
- Page 273 and 274:
262 Tashkin and Roth given intraper
- Page 275 and 276:
264 Tashkin and Roth Table 4 Associ
- Page 277 and 278:
266 Tashkin and Roth tumor growth.
- Page 279 and 280:
268 Tashkin and Roth methylxanthine
- Page 281 and 282:
270 Tashkin and Roth users are impa
- Page 283 and 284:
272 Tashkin and Roth 26. Tashkin, D
- Page 285 and 286:
274 Tashkin and Roth 62. Galiegue S
- Page 287 and 288:
276 Tashkin and Roth
- Page 289 and 290:
278 Logan experience as producing a
- Page 291 and 292:
280 Logan ational marijuana user (a
- Page 293 and 294:
282 Logan Table 1 Relationship Betw
- Page 295 and 296:
284 Logan Table 2 Mean, Median, and
- Page 297 and 298:
286 Logan 2.1.1.4. SUMMARY Blood co
- Page 299 and 300:
288 Logan Table 4 Summary of Odds R
- Page 301 and 302:
290 Logan age preferred dose to ach
- Page 303 and 304:
292 Logan REFERENCES 1. Papafotiou,
- Page 305 and 306:
294 Logan
- Page 307 and 308:
296 Karch Fig. 1. Current breakdown
- Page 309 and 310:
298 Karch The authors of the study
- Page 311 and 312:
300 Karch quantitation (32), THC’
- Page 313 and 314:
302 Karch
- Page 315 and 316:
304 Musty most objective test of th
- Page 317 and 318:
306 Musty 2.3. A Good Safety and To
- Page 319 and 320:
308 Musty was measured using the ra
- Page 321 and 322:
310 Musty Zajicek et al. (25) evalu
- Page 323 and 324:
312 Musty Consroe et al. (31) found
- Page 325 and 326:
314 Musty 5. Foltin, R. W., Brady,
- Page 328 and 329:
Index AcompliaTM, see Rimonabant Ac
- Page 330 and 331:
Index 319 Cloned enzyme donor immun
- Page 332 and 333:
Index 321 Nefazodone, marijuana wit